Ask the expert. Does antibody induction therapy with daclizumab or basiliximab increase the risk of recurrence of post-transplant focal segmental glomerulosclerosis?
Gagnadoux
Marie-France
MF
Pediatric Nephrology, Hôpital Necker-Enfants-Malades, 149 rue de Sèvres, 75743 Paris Cedex 15, France. marie-france.gagnadoux@nck.ap-hop-paris.fr
D000911:Antibodies, Monoclonal / Q000009:adverse effects*; D061067:Antibodies, Monoclonal, Humanized; D000077552:Basiliximab; D000077561:Daclizumab; D005923:Glomerulosclerosis, Focal Segmental / Q000601:surgery*; D006801:Humans; D007074:Immunoglobulin G / Q000009:adverse effects*; D007166:Immunosuppressive Agents / Q000009:adverse effects*; D007167:Immunotherapy / Q000009:adverse effects*; D016030:Kidney Transplantation / Q000009:adverse effects*; D011993:Recombinant Fusion Proteins; D012008:Recurrence; D012307:Risk Factors
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D007074:Immunoglobulin G; D007166:Immunosuppressive Agents; D011993:Recombinant Fusion Proteins; D000077552:Basiliximab; D000077561:Daclizumab